Geranylgeranylacetone as prevention for postoperative Atrial Fibrillation (GENIALITY trial)

29 August 2025 (12:15 - 13:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Kennedy Silva Ramos

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail

How does artificial intelligence-derived electrocardiographic age and sex predict recurrence outcomes after atrial fibrillation catheter ablation?

Doctor H. Park (Seoul, KR)

Abstract Slides Video

Presentation thumbnail

The role of pulmonary vein anatomy in predicting atrial arrhythmia recurrence after pulsed-field ablation

Mr M. Mutti (Basel, CH)

Abstract Slides Video

Presentation thumbnail

The impact of atrial fibrillation progression on the epicardial adipose tissue volume: supporting 'AF begets EAT' theory

Doctor K. Shimojo (Ogaki, JP)

Abstract Slides Video

Presentation thumbnail

Common genetic variants associated with characteristics and clinical outcomes of atrial fibrillation: from a large population based registry (FinnGen)

Doctor A. Maan (Toledo, US)

Abstract Slides Video

Presentation thumbnail

Impact of low hemoglobin levels on arrhythmia recurrence after radiofrequency catheter ablation of atrial fibrillation

Doctor Y. Matsunaga (Sakai, JP)

Abstract Slides Video

Access the full session

Session thumbnail

Prediction of atrial fibrillation recurrences: still a challenge

The Event

Event poster

ESC Congress 2025

29 August 2025 12:15 CET

You may be interested in

Congress Presentation

GenePHIT phase 2 study design: a double blind, placebo-controlled trial to assess efficacy, safety, and tolerability of AB-1002 gene therapy in adults with heart failure

Congress Session

HOT LINE 5

Congress Presentation

GLADIATOR: The effects of geranylgeranylacetone in patients with HFpEF

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources